会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 62. 发明授权
    • Active electrode for transdermal medicament administration
    • 用于透皮药物给药的活性电极
    • US08197844B2
    • 2012-06-12
    • US11811241
    • 2007-06-08
    • Jamal S. Yanaki
    • Jamal S. Yanaki
    • A61F13/00A61F13/02A61B5/04
    • A61N1/30A61F13/00051A61F13/02A61F2013/00285A61F2013/00417A61F2013/00442A61F2013/00489A61F2013/00646A61F2013/00906A61F2013/00919A61F2013/00948A61F2013/00961
    • A transdermal medicament patch includes a biocompatible substrate having a therapeutic face on one side configured for disposition against the skin of a patient, a biocompatible adhesive on the therapeutic face, a planar medicament matrix covering a portion of the therapeutic face, and a release liner covering the portion of therapeutic that is not obscured by the medicament matrix. An aperture formed through the release sheet affords direct access by medicament to the entire surface of the medicament matrix opposite from the therapeutic face of the substrate. An active electrode positioned between the medicament matrix and the therapeutic face of the substrate includes an electrically conductive backing layer positioned against the therapeutic face of the substrate and a pH-control layer covering less than all of the side of the backing layer opposite from the therapeutic face of the substrate. One active electrode design criterion relates the relative size of the pH-control layer to the size of the backing layer; another relates the size of portion of the area of the backing layer that is free of the pH-control lawyer to the size of the pH-control layer. The pH-control layer is made of an electrically conductive material capable of moderating changes in the hydrogen-ion concentration in the medicament matrix during iontophoretic current flow. An electrical contact electrically coupled through the substrate to the backing layer includes a hollow, electrically conductive snap fitting having an open end and a cooperating stud that is inserted into the open end of the snap.
    • 透皮药物贴片包括生物相容性基底,其具有在一侧上的治疗面,其配置用于处置患者的皮肤,治疗面上的生物相容性粘合剂,覆盖治疗面部分的平面药物基质和释放衬垫覆盖物 不被药物基质遮蔽的治疗部分。 通过剥离片形成的孔可以通过药物直接进入与基底的治疗面相反的药物基质的整个表面。 位于药物基质和基底的治疗面之间的有源电极包括抵靠基底的治疗面定位的导电背衬层和覆盖与治疗组相反的背衬层全部侧面的pH控制层 基材面。 一个活性电极设计标准将pH控制层的相对尺寸与背衬层的尺寸相关; 另一个涉及不含pH控制律师的背衬层的面积的部分尺寸与pH值控制层的尺寸。 pH控制层由能够调节离子电渗电流期间药物基质中氢离子浓度变化的导电材料制成。 通过基底电耦合到背衬层的电触点包括具有开口端的中空的导电卡扣配件,以及插入卡扣的开口端的协作钉。
    • 66. 发明申请
    • TRANSDERMAL MEDICAMENT PATCH AND ACTIVE ELECTRODE FOR SAME
    • 用于同种异体的药物传递物质和活性电极
    • WO2008153931A3
    • 2009-03-12
    • PCT/US2008007109
    • 2008-06-06
    • ACTIVATEK INCYANAKI JAMAL S
    • YANAKI JAMAL S
    • A61N1/30
    • A61N1/30A61F13/00051A61F13/02A61F2013/00285A61F2013/00417A61F2013/00442A61F2013/00489A61F2013/00646A61F2013/00906A61F2013/00919A61F2013/00948A61F2013/00961
    • A transdermal medicament patch (18,0168) includes a substrate(32, 172) having a therapeutic face (40, 180) configured for disposition against the skin (102), an adhesive on the therapeutic face (40, 180), a planar medicament matrix (46, 188) covering a portion of the therapeutic face (46,188), and a release liner (41, 182) covering the portion of therapeutic face (40, 180) not obscured by the medicament matrix (46, 188) An aperture (44, 186) through the release liner (41, 182) affords access to the medicament matnx (46, 188) An active electrode (54, 110, 120, 130, 140, 150, 210, 230, 250,270, 290) positioned between the medicament matrix (46,188) and the therapeutic face (40, 180) includes an electpcally conductive backing layer (56, 142, 152,212,232,252,272, 292) positioned against the therapeutic face (40, 180) and a pH-control layer (58, 132, 146, 156,216, 236, 256, 276, 296) that moderates changes in hydrogen-ion concentration covering
    • 透皮药物贴剂(18,0168)包括具有配置用于处置皮肤(102)的治疗面(40,180)的基底(32,172),治疗面(40,180)上的粘合剂,平面 覆盖治疗面(46,188)的一部分的药物基质(46,188)和覆盖治疗面(40,180)部分的释放衬垫(41,182),其不被药物基质(46,188)遮蔽。 通过释放衬垫(41,182)的孔径(44,186)可以进入药物基质(46,188)。有效电极(54,110,120,130,140,​​150,210,230,250,270,290) 位于药物基质(46,188)和治疗面(40,180)之间的电极包括位于治疗面(40,180)和pH控制层(58)上的电导电背衬层(56,142,152,212,232,252,272,292) ,132,146,156,216,236,256,276,296),其缓和了氢离子浓度的变化
    • 67. 发明申请
    • TRANSDERMAL MEDICAMENT PATCH AND ACTIVE ELECTRODE FOR SAME
    • 用于同种异体的药物传递物质和活性电极
    • WO2008153931A2
    • 2008-12-18
    • PCT/US2008/007109
    • 2008-06-06
    • ACTIVATEK, INC.YANAKI, Jamal, S.
    • YANAKI, Jamal, S.
    • A61B5/04A61F13/00A61F13/02
    • A61N1/30A61F13/00051A61F13/02A61F2013/00285A61F2013/00417A61F2013/00442A61F2013/00489A61F2013/00646A61F2013/00906A61F2013/00919A61F2013/00948A61F2013/00961
    • A transdermal medicament patch ( 18,0168) includes a substrate(32, 172) having a therapeutic face (40, 180) configured for disposition against the skin (102), an adhesive on the therapeutic face (40, 180), a planar medicament matrix (46, 188) covering a portion of the therapeutic face (46,188), and a release liner (41, 182) covering the portion of therapeutic face (40, 180) not obscured by the medicament matrix (46, 188). An aperture (44, 186) through the release liner (41, 182) affords access to the medicament matrix (46, 188). An active electrode (54, 110, 120, 130, 140, 150, 210, 230, 250, 270, 290) positioned between the medicament matrix (46, 188) and the therapeutic face (40, 180) includes an electrically conductive backing layer (56, 142, 152, 212, 232, 252, 272, 292) positioned against the therapeutic face (40, 180) and a pH-control layer (58, 132, 146, 156, 216, 236, 256, 276, 296) that moderates changes in hydrogen-ion concentration covering less than all of the therapeutic face (40, 180). One active electrode design criterion relates the size of the pH-control layer to the size of the backing layer; another relates the size of the portion of the backing layer not covered by the pH-control layer to the size of the pH-control layer.
    • 透皮药物贴剂(18,0168)包括具有配置用于处置皮肤(102)的治疗面(40,180)的基底(32,172),治疗面(40,180)上的粘合剂,平面 覆盖治疗面(46,188)的一部分的药物基质(46,188)和覆盖治疗面部(40,180)的部分而不被药物基质(46,188)遮蔽的释放衬垫(41,182)。 穿过释放衬垫(41,182)的孔(44,186)可以进入药物基质(46,188)。 位于药物基质(46,188)和治疗面(40,180)之间的有源电极(54,110,120,130,140,​​150,210,230,250,270,290)包括导电背衬 定位在治疗面(40,180)和pH控制层(58,132,146,156,216,236,256,276)之间的层(56,142,152,212,232,252,272,292) ,296),其缓和氢离子浓度的变化,其覆盖率小于所有治疗面(40,180)。 一个活性电极设计标准将pH控制层的尺寸与背衬层的尺寸相关联; 另一个涉及未被pH控制层覆盖的背衬层的部分的尺寸与pH值控制层的尺寸。